Ann: Drug Candidate Demonstrates Significant Cardioprotection, page-33

mate you should post that on AGN lol Passed their safety studies and valued at a 110 million market cap. AGN just passed their invivo and in vitro micronucleus studies on Monday. GLP tests the human genome, human CNS and human cardiovascular system.

Right now NYR are the only drug in the world in this drug class that’s on its way to become one if the first drugs to treat TBI and stroke but also the only drug class to become far superior than Ace inhibitors. 18 million market cap it’s still got a lot of rerating to go and it’s called investing into the future and the future is strong for NYR